Mitsubishi Tanabe to pay about $151mm for 54% stake in Medicago
Executive Summary
Mitsubishi Tanabe Pharma Corp. is acquiring the majority ownership (54%) of public Canadian firm Medicago Inc. (infectious disease vaccines) for $1.10 ($Cdn1.16) in cash per share (a 29% premium), valuing the transaction at $151mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice